Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus (T2DM)
• Intervention / Treatment: Drug: Placebo; Drug: PE0139 Injection

• Study Type: Interventional
• Enrollment (Actual): 37
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Anniston, Alabama, United States, 36207
      • Pinnacle Research Group, LLC
  • Florida
    • Hialeah, Florida, United States, 33012
      • Palm Springs Research Institute
  • Washington
    • Renton, Washington, United States, 98057
      • Rainier Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing and able to sign a written informed consent and follow all study-related procedures;
• Male and female subjects at least 18 years of age;
• Male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their dose of study drug;
• Body mass index ≤45 kg/m2;
• Diagnosed with T2DM and who is currently taking a stable daily dose of a basal insulin (Lantus) plus at least one oral antihyperglycemic agent at a stable dose for 3 months prior to screening.

Exclusion Criteria:

• Currently taking or have taken within 3 months prior to screening an approved or investigational GLP-1 analogue/agonist (e.g., Victoza®) or pramlintide;
• Currently taking or have routinely taken, within 3 months prior to screening , a short-acting insulin;
• Currently taking or have taken, within 3 months prior to screening, a long acting insulin other than Lantus®;
• Known allergy to, or serious adverse effect caused by an approved, or investigational insulin product or any of its components;
• Currently taking any of the following medications: thiazide or furosemide diuretics, beta-blockers, estrogens or other hormonal replacement therapy, or other chronic medications with known adverse effects on glucose tolerance levels unless the subject has been on stable doses of such agents for at least 2 months prior to screening and have no planned changes during the study period;
• History of recurrent severe hypoglycemia (more than 2 episodes within the last 6 months prior to randomization or hypoglycemic unawareness;
• Malignant disease defined as 1) any history of malignant melanoma or breast cancer and/or 2) history of other types of cancer within the last 5 years prior to screening;
• Unstable cardiovascular disease defined as one or more of the following: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to screening; History of or currently have New York Heart Association Class III-IV heart failure prior to screening; Uncontrolled/sustained hypertension; History or evidence of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT interval;
• Clinically significant renal and/or hepatic dysfunction;
• Absolute requirement for corticosteroids or have received systemic steroids within 3 months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical corticosteroids will be permitted;
• Pregnant or lactating female subjects;
• Known history of or active alcohol abuse or use of illicit drugs within 1 year prior to screening;
• Positive screening for human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies at V1;
• Participating in any other study and have received any other investigational medication or device within 30 days prior to Visit 1.
• Other medical or psychiatric condition which, in the opinion of the Investigator, would place the subject at increased risk.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PE0139 Injection; Single subcutaneous injection of PE0139, 40 mg/mL	Drug: PE0139 Injection
Placebo Comparator: Placebo; Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Vital Signs from baseline (Day 0 Pre-dose)	Safety will be evaluated by analyses of the change from baseline in vital signs.	Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28
Change in ECGs from baseline (Day -1)	Safety will be evaluated by analyses of the change from baseline in 12-lead ECG.	ECG Days 2 and 28
Change in Safety Labs from baseline (Pre-dose)	Safety will be evaluated by analyses of the safety laboratory parameters.	Safety Labs Days 0, 7 and 28
Incidence and severity of immunogenicity	Safety will be evaluated by the incidence and severity of immunogenicity.	Immunogenicity Days 0, 7, 14 and 28
Incidence and severity of adverse events including hypoglycemia	Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia.	As reported between Days -10 to 28

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Profile	Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F)	Day 0, 1, 2, 3, 4, 5, 6, and 7
Pharmacodynamic Response	To assess the pharmacodynamic response (time action profile) of various single doses of PE0139. Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM).	FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7

Collaborators and Investigators

• Sponsor: PhaseBio Pharmaceuticals Inc.
• Investigators: Principal Investigator: Ronald Brazg, MD, Rainier Clinical Research

Study record dates

Study Major Dates

• Study Start: April 1, 2013
• Primary Completion (Actual): May 1, 2014
• Study Completion (Actual): May 1, 2014

Study Registration Dates

• First Submitted: March 28, 2013
• First Submitted That Met QC Criteria: April 16, 2013
• First Posted (Estimate): April 19, 2013

Study Record Updates

• Last Update Posted (Estimate): October 15, 2014
• Last Update Submitted That Met QC Criteria: October 13, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: PE0139-PT-CL-0001